The Latest Breaking News on Pharma

From yesterday's decision by Judge Gregory Woods (S.D.N.Y.) in Cassava Sciences, Inc. v. Bredt: Cassava Sciences, Inc. ("Cassava") is a biotechnology company that is conducting clinical trials for an Alzheimer's drug called simufilam. Following the second phase of the simufilam clinical trials, multiple short sellers, most of them scientists, published…

Exclusive: Millions more GP appointments potentially created as a result of closures

Some Medicare beneficiaries may pay lower coinsurance rates from April 1 to June 30 for the drugs, HHS says.

Abortion opponents are citing the Comstock Act to stop "abortion pill trafficking." Experts say that's nonsense

Biotech firm C4X today became the latest business to abandon the London stock market after is said its future growth would be better secured through private investment.

U.S. Supreme Court justices on Tuesday did not appear ready to limit access to the abortion pill mifepristone, in a case that could have far-reaching implications for millions of American women and for scores of drugs regulated by the Food and Drug Administration.

"It would be a catastrophic event."

The Supreme Court's upcoming decision on mifepristone's approval process could have significant implications for reproductive rights and healthcare access ...

A majority of Supreme Court justices seemed open to keeping mifepristone, a common abortion-inducing drug, on the market despite a Texas ruling revoking its FDA approval.

A ruling against expanded mifepristone access could set a precedent for courts to substitute their own conclusions for agency decisions.

The mifepristone case is viewed with trepidation by the medical industry and could have enormous consequences for drug regulation